Dr Alex Alderton | Head of Cellular Operations

Alderton, Alex

Alex is the Head of Cellular Operations at the Wellcome Sanger Institute. In this role she leads a team of 55 scientists covering a broad range of scientific areas including flow cytometry, CRISPR genome editing, stem cells, high content imaging and organoid derivation. Collectively, the team provide cell biology expertise to help deliver some of the institutes largest and most ambitious projects.

Alex has a background in cell and molecular biology, in particular the development of cell lines and assays for large scale or high throughput science. She completed a Post doc on prion-based neurological disorders at the University of Bath in 2006 before joining Pfizer to work in cell line and assay development for a variety of early stage drug discovery projects. In 2012, Alex move to the Sanger to take up a senior role in the newly formed Cellular Generation and Phenotyping (CGaP) core facility, where she went onto become the facility head in 2015. In 2017, Alex moved into her current role as Head of Cellular Operations.


  • Single-cell RNA-sequencing of differentiating iPS cells reveals dynamic genetic effects on gene expression.

    Cuomo ASE, Seaton DD, McCarthy DJ, Martinez I, Bonder MJ et al.

    Nature communications 2020;11;1;810

Alderton, Alex
Alex's Timeline

Head of Cellular Operations at the Sanger Institute


Head of Cellular Generation and Phenotyping at the Sanger Institute


Senior Scientific Manager at the Sanger Institute


Principal Scientist, Research Enabling Group at Pfizer


Senior Scientist, Primary Pharmacology Group at Pfizer


Screening Scientist, Primary Pharmacology Group at Pfizer


Post Doc at University of Bath


PhD in Molecular Biology, University of Kent